Cardiovascular Health

Discover how objective activity monitoring with accelerometers transforms cardiovascular risk assessment and treatment evaluation, enhancing patient care for pharmacists.

Hypertensive disorders of pregnancy confer increased cardiovascular risk, with heightened risk corresponding to more severe hypertension.

Expert highlights the benefits of early combination therapy in hypertension management, emphasizing improved blood pressure control and reduced side effects.

Heart failure prevention can be integrated into health systems to optimize care.

Expert reveals ongoing disparities in heart valve disease care, stressing the need for improved diagnosis and treatment equity for vulnerable populations.

Boehringer Ingelheim showcases its commitment to cardio-kidney-metabolic research, highlighting innovative therapies and advancements at AHA 2025.

Discover how emerging therapies in cardio-kidney-metabolic health reshape disease management at AHA 2025, highlighting interconnected health pathways.

A new wrist-worn accelerometer device effectively monitors activity levels in heart failure patients, revealing critical insights into cardiovascular health.

Explore the critical role of pharmacists in improving cardiovascular health and addressing mortality trends in underserved communities.

A new drug, DR10624, shows promise in reducing triglycerides and liver fat, offering hope for patients with severe hypertriglyceridemia and fatty liver disease.

Explore the link between chronic kidney disease and cardiovascular risk, highlighting the importance of GFR and albuminuria in patient care.

Explore the need for integrated approaches in cardiovascular and kidney health to combat rising mortality rates and improve patient outcomes.

Discover how Sotatercept impacts cardiovascular health and its potential benefits for patients with pulmonary arterial hypertension (PAH) in this insightful article.

Pharmacists play a vital role in managing cardiovascular health, addressing medication adherence, and educating patients, said Zia Ul Haq, MPH, MBBS.

SGLT2 inhibitors significantly reduce atrial fibrillation risk and improve heart failure outcomes, outperforming GLP-1 agonists in cardiovascular benefits.

Maintaining cardiovascular health significantly reduces dementia risk in adults with type 2 diabetes, highlighting the heart-brain connection for cognitive protection.

Combining GLP-1 RA therapy with healthy lifestyle habits significantly reduces cardiovascular risk in type 2 diabetes patients, enhancing heart health outcomes.

Craig Beavers and Kyle Fischer, PharmD, BCCP, MBA, discuss key late-breaking cardiovascular trials expected at the American Heart Association’s upcoming annual meeting, exploring their clinical relevance and implications for pharmacists.

Long-term melatonin use for insomnia raises heart failure risks, highlighting the need for careful evaluation of sleep aids and underlying health issues.

Teva Pharmaceuticals recalls over 580,000 bottles of prazosin due to contamination concerns, urging patients to consult healthcare providers.

Richard Kovacs, MD, underscores the pharmacist’s role in educating patients about sodium reduction, monitoring blood pressure, and ensuring safe transitions to low-sodium oxybate therapy.

Richard Kovacs, MD, explains how switching from high-sodium to low-sodium oxybate led to meaningful blood pressure reductions and lower cardiovascular risk in patients with narcolepsy.

In Danish athletes, long-term anabolic androgenic steroid use was associated with progressively worsened cardiovascular outcomes.

The FDA updates sotatercept's label, enhancing treatment options for pulmonary arterial hypertension and reducing severe clinical events.